Stockscreener 앱 받기
1.00
14.35%
-0.1675
전일 마감가:
$1.1675
열려 있는:
$0.94301
하루 거래량:
17,436
Relative Volume:
16.03
시가총액:
$N/A
수익:
-
순이익/손실:
$-9.57M
주가수익비율:
-1.0621
EPS:
-0.9415
순현금흐름:
$-6.66M
1주 성능:
-14.35%
1개월 성능:
-14.35%
6개월 성능:
+87.27%
1년 성능:
-87.10%
1일 변동 폭
$0.922
$1.08
1주일 범위
$0.922
$1.08
52주 변동 폭
$0.534
$1.19
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Compare BCLI vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.00 | 0 | 0 | -9.57M | -6.66M | -0.9415 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-02-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-11-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-12-19 | 재확인 | Maxim Group | Buy |
| 2015-12-22 | 재확인 | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc 주식(BCLI)의 최신 뉴스
Brainstorm Cell Therapeutics Stock Price Forecast. Should You Buy BCLI? - StockInvest.us
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions - Yahoo Finance
Brainstorm Cell Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pitts Peter Joe - Moomoo
BrainStorm Cash Drops to $0.2 Million, Raising Going-Concern Risk - Minichart
Brainstorm Cell Therapeutics (BCLI) posts loss and warns on going concern - Stock Titan
BCLI: Phase 3b ALS trial preparations advance as net loss widens and new capital is secured - TradingView
BrainStorm Posts $3.9 Million Second-Quarter Net Loss as NurOwn Trial Preparations Continue - Quiver Quantitative
Brainstorm Cell Therapeutics | 8-K: BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Lunai Bioworks signs collaboration with BrainStorm Therapeutics By Investing.com - Investing.com South Africa
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027 - PR Newswire
Brainstorm Appoints Former FDA Associate Comm - Moomoo
BrainStorm Cell Reshapes Leadership to Advance NurOwn Trial - TipRanks
Form 4 Brainstorm Cell Therapeutics Inc For: 28 July By Investing.com - Investing.com Nigeria
BrainStorm Cell (BCLI) grants 100,000 RSUs to director Frenkel - Stock Titan
Brainstorm Cell Therapeutics Inc. Announces Executive and Board Changes - marketscreener.com
BrainStorm names ex-FDA official Pitts as executive chairman By Investing.com - Investing.com Canada
BrainStorm's ALS Trial Set to Launch Under First-Ever Special Protocol Assessment - Stock Titan
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman - Prime Publishers, Inc.
CYVNY Stock Price and Chart — OTC:CYVNY - TradingView
Peter Joe Pitts Net Worth (2026) - GuruFocus
Price to earnings forward of BrainStorm Cell Therapeutics Inc. – OTC:BCLI - TradingView
Price to earnings forward of Brainstorm Cell Therapeutics Inc. – SWB:GHD - TradingView
Brainstorm Cell Therapeutics (BCLI) Status Update Summary - Quartr
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Brainstorm Cell Therapeutics Inc. Actuals & Estimates (OTC:BCLI) - TradingView
Brainstorm Cell Therapeutics Inc (BCLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Institutional Confidence - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Brainstorm Cell Therapeutics Inc - TradingKey
BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN
Brainstorm leaders urge FDA to update treatment review process - ALS News Today
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (BCLI) Stock Price, Quote, News & History - Benzinga
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Thera - Barchart.com
The Escalator: VML Health, BrainStorm Cell Therapeutics, Syneos Health and more - Medical Marketing and Media
Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant - Stock Titan
[EFFECT] BRAINSTORM CELL THERAPEUTICS INC. SEC Filing - Stock Titan
BrainStorm Cell Therapeutics Announces Publication Calling for U - GuruFocus
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - PR Newswire
BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay - Stock Titan
BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant - Stock Titan
Officer at Brainstorm Cell (NASDAQ: BCLI) awarded 100,000 RSUs - Stock Titan
BrainStorm Cell (NASDAQ: BCLI) director receives 200,000 RSUs as stock award - Stock Titan
Brainstorm Cell (BCLI) director receives 120,000-share RSU award - Stock Titan
BrainStorm Cell Therapeutics Inc. Appoints Peter J. Pitts to Board of Directors, Effective May 29, 2026 - marketscreener.com
Gene and Cell Therapies Targeting CNS Disorders Market - openPR.com
Brainstorm Cell Therapeutics Inc (BCLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.48%
0.31%
자본화:
|
볼륨(24시간):